Navigation Links
Echo Therapeutics Unveils Symphony tCGM Demonstration Video
Date:8/9/2011

PHILADELPHIA, Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at www.echotx.com.  The new video showcases the features and ease of use of the Symphony continuous glucose monitoring system in a home setting.  The Company has released this demonstration video as a result of increasing demands from patients and investors for information regarding how the Symphony tCGM System works.

The launch of the video coincides with the final steps in the planning and preparation of the upcoming clinical study testing the next generation Symphony tCGM System design, which will commence in the near-term.  

"We are excited to feature the demonstration video on our website in order to illustrate the ease of using Symphony. We believe that Symphony will be an important and differentiated candidate for glucose monitoring that has the potential to change the paradigm of invasive, episodic glucose monitoring.  We believe that the ease of use and needle-free, wireless and continuous features and benefits will improve patient compliance to frequent glucose testing and lead to better long term outcomes for patients," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "More than ever, we are enthusiastic about the potential of Symphony and we look forward to the commencement of the upcoming clinical study."

About Continuous Glucose Monitoring (CGM)

Continuous glucose monitoring has the potential to help plan diabetes treatment, guide day-to-day choices about diet, exercise and insulin use, and avoid unwanted low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia) events and the complications that they can cause. Blood glucose levels are affected by many factors such as the carbohydrate and fat content of food, exercise, stress, illness, and variability in insulin absorption among others; therefore, it is often challenging for diabetes patients to avoid frequent and unpredictable excursions above or below normal glucose levels. Patients are often unaware that their glucose levels are either too high or too low, resulting in their inability to control their glucose levels and prevent the complications associated with unwanted glucose excursions.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Corporate Communications
(215) 717-4104

Connect With Us:

- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
2. Echo Therapeutics Announces Multiple Patents and Trademark Grants
3. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
4. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
5. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
6. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
7. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
9. Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
10. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
11. Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Vitasome ® ... of nutritional supplements using its groundbreaking new liposome technology. ... percent of potency through digestion per Physician,s Desk ... solve the problem of nutritional waste and are scientifically ... during digestive processes Improve bioavailability with ...
(Date:2/27/2017)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced that ... Raymond James and Associates, 38 th Annual ... Orlando, FL. Cowen and Company ... March 7, 2017 in Boston, MA. ... in Miami, FL. Individuals ...
(Date:2/27/2017)... -- Leading Countries, Technologies and Companies ... at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% ... of 9.1% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... , ... Elisa Guajardo Carothers is not your typical author. She went from working as a ... she writes about God, when she isn’t swimming as a performing mermaid. , Her book ... (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before Lucifer ...
(Date:2/27/2017)... , ... February 26, 2017 , ... Miro is the ... sound and video system brings songs, movies, TV shows and much more apps for ... clear, high-definition sound. An immersive view of 1280 x 720 provides crisp images with ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
Breaking Medicine News(10 mins):